- Home
- GDL vs LONA Comparison
GDL vs LONA Comparison
Compare GDL & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
N/A
Current Price
$9.79
Company Overview
Basic Information| Metric | GDL | LONA |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | United States |
| Employees | N/A | 26 |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.7M | 83.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GDL | LONA |
|---|---|---|
| Price | $8.34 | $9.79 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 10.1K | ★ 75.5K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 6.02% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.81 | $4.21 |
| 52 Week High | $8.67 | $14.21 |
Technical Indicators
Market Signals| Indicator | GDL | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 55.50 | 56.57 |
| Support Level | $8.39 | $4.52 |
| Resistance Level | $8.47 | $14.21 |
| Average True Range (ATR) | 0.10 | 1.37 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 67.12 | 35.81 |
Price Performance
Historical Comparison GDL
LONA
About GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.
About LONA LeonaBio Inc. Common Stock
LeonaBio Inc is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS).